



Co-funded by
the European Union



ROBERT KOCH INSTITUT



Joint Action EUCanScreen

Hella Fügemann, Klaus Kraywinkel

Centre for Cancer Registry Data

German Cancer Congress

February 18, 2026



Key Facts JA EUCanScreen

- **Duration:** June 2024 - May 2028 (48 months)
- **Project coordination:** University of Latvia
- **Participation:** 25 EU member states + Ukraine, Moldova, Norway and Iceland
- **Funding amount** of the project: EUR 38,749,935
- **Funding code:** 101162959
- <https://eucanscreen.eu/>

Participating institutions from Germany

- Robert Koch-Institute (RKI, Competent Authority)
- German Cancer Society (DKG)
- German Cancer Research Center (DKFZ)
- The Leibniz Institute for Prevention Research and Epidemiology - BIPS
- MSB Medical School Berlin



Aims of the Joint Action

- Implementation and further development of evidence-based, high-quality screening programs for breast, cervical, and colorectal cancer
- Research into the assessment and implementation of new screening programs for lung, prostate, and stomach cancer
- Ensuring better quality, more up-to-date, and more comparable data collection and monitoring of screening programs, as well as improving knowledge exchange between European countries
- Reducing the overall burden of cancer and increasing equal access to screening programs



11 Work packages

WP 1: Coordination

WP 2: Dissemination

WP 3: Evaluation

WP 4: Sustainability

WP 5: Monitoring

WP 6: Addressing barriers and
facilitators in cancer screening

WP 7: Implementation research
to improve the existing screening
programs

WP 8: Facilitation of the new
screening approach
implementation

WP 9: Risk-based
Approaches

WP 10: Modelling and health
technology assessment

WP 11: Capacity-Building

[https://eucanscreen.eu/
workpackages/](https://eucanscreen.eu/workpackages/)

11 Work packages

WP 1: Coordination

WP 2: Dissemination

WP 3: Evaluation

WP 4: Sustainability

WP 5: Monitoring

WP 6: Addressing barriers and
facilitators in cancer screening

WP 7: Implementation research
to improve the existing screening
programs

WP 8: Facilitation of the new
screening approach
implementation

WP 9: Risk-based
approaches

WP 10: Modelling and health
technology assessment

WP 11: Capacity-building

[https://eucanscreen.eu/
workpackages/](https://eucanscreen.eu/workpackages/)

WP 6.5: German Cancer Society is Task-Leader

- Improving cancer screening for people with intellectual disabilities



Scoping Review

Current evidence on barriers, enabling factors, and interventions



Expert Interviews

Analysis of recommended practices from European countries



Register Analysis

Analysis of Norwegian screening data on participation rates



Feasibility Study

on the acceptance of self-sampling strategies for HPV testing in Belgium




WP 6: Initiation and coordination of the “Turin Memorandum” in May 2025

- **Joint consensus** on improving cancer screening for people with intellectual disabilities
- 25 signing experts from 13 countries
- **Core element:** annual national survey on data availability, measures, and reasonable adjustments in relation to the target group among the competent health authorities
- **Results report** for the first survey in 2025 is almost completed





WP 6: Translation and adaptation of easy-to-read brochures on cancer screening into other easy-to-read languages and national contexts



Deutsche Krebsgesellschaft e. V. / Lebenshilfe e. V. 2022

11 Work packages

WP 1: Coordination

WP 2: Dissemination

WP 3: Evaluation

WP 4: Sustainability

WP 5: Monitoring

WP 6: Addressing barriers and
facilitators in cancer screening

WP 7: Implementation research
to improve the existing screening
programs

WP 8: Facilitation of the new
screening approach
implementation

WP 9: Risk-based
approaches

WP 10: Modelling and health
technology assessment

WP 11: Capacity-building

[https://eucanscreen.eu/
workpackages/](https://eucanscreen.eu/workpackages/)



WP 5: BIPS participation in tasks dealing with data availability and data standardization

- **Aim:** Improve comparison and research using data from screening programs and enable this across European borders → Common Data Models for breast, cervical, and colorectal cancer screening
- **Results so far:** Previous definitions are sometimes too restrictive for the data available in Germany; in some cases, they do not adequately reflect the heterogeneity of screening programs in different countries



WP 8: Involvement of BIPS and DKFZ in task to implement risk-adapted prostate cancer screening

- **Feasibility study** on the use of capillary blood for PSA measurement and related testing of additional (low-threshold) approaches to screening
 - BIPS: Selected pharmacies (Bremen)
 - DKFZ: National Cancer Prevention Center (Heidelberg)
- **Online survey** to evaluate factors that facilitate or hinder participation in screening
- **Current status:** Preparations for pilot study completed



WP 9: Involvement of BIPS in the development of a joint concept for risk-based screening

- Participation in two **DELPHI rounds**
- Conducting a **survey** on the acceptance of risk-based screening among the population
- **Current status:** Concept paper on risk-based screening agreed within the work package



(Preliminary) Conclusion

- Opportunity to share experiences and knowledge at an international level
 - Method development
 - Comparability and harmonization of data
 - Evaluation of screening programs
 - Visibility of deficits